Organigram Global (OGI) Cash from Financing Activities (2018 - 2026)
Organigram Global (OGI) posted quarterly Cash from Financing Activities of -$6.0 billion for Q1 2026, down 162.24% year-over-year from $9.6 billion in Q1 2025, and down 1856987.03% quarter-over-quarter from -$322688.8 in Q4 2025.
Organigram Global (OGI) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Cash from Financing Activities for 7 consecutive years, with -$6.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 162.24% year-over-year to -$6.0 billion; the TTM figure through Mar 2026 stood at $3.6 billion (up 111.03% YoY), while the FY2025 annual figure was $28.6 million, down 63.83% from the prior year.
- Cash from Financing Activities retreated to -$6.0 billion in Q1 2026 per OGI's latest filing, from -$322688.8 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $9.6 billion in Q1 2025 and bottomed at -$6.0 billion in Q1 2026.
- Historically, Cash from Financing Activities has averaged $908.9 million across 3 years, with a median of -$233645.2 in 2024.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities plunged 123.16% — and 2026, when it sank 162.24%.
- Organigram Global's Cash from Financing Activities stood at -$144601.5 in 2024, then slumped by 123.16% to -$322688.8 in 2025, then plunged by 1856987.03% to -$6.0 billion in 2026.
- Business Quant data shows OGI's Cash from Financing Activities at -$6.0 billion in Q1 2026, -$322688.8 in Q4 2025, and $9.6 billion in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Organigram Global | 150.66 Mn | 150.54 Mn | 28.97 Mn | -657,014.33 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.99 Bn |
| Mar 31, 2026 | -5.99 Bn |
| Dec 31, 2025 | -322,688.83 |
| Dec 31, 2025 | -322,688.83 |
| Mar 31, 2025 | 9.63 Bn |
| Mar 31, 2025 | 9.63 Bn |
| Dec 31, 2024 | -144,601.53 |
| Dec 31, 2024 | -144,601.53 |
| May 31, 2021 | 174.41 Mn |
| May 31, 2021 | 174.41 Mn |
| Feb 28, 2021 | -42.78 Bn |
| Feb 28, 2021 | -42.78 Bn |
| Nov 30, 2020 | 79.30 Bn |
| Nov 30, 2020 | 79.30 Bn |
| Aug 31, 2020 | 34.29 Mn |
| Aug 31, 2020 | 34.29 Mn |
| May 31, 2020 | 3,555.00 |
| May 31, 2020 | 3,555.00 |
| Feb 29, 2020 | 86.61 Mn |
| Feb 29, 2020 | 86.61 Mn |